Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy

Journal of Ultrasound in Medicine

Volumn 31, Issue 10, 2012, Pages 1543-1550

  Sorace, Anna G ^a   Saini, Reshu ^a   Mahoney, Marshall ^a   Hoyt, Kenneth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Contrast enhanced ultrasound; Microbubbles; Targeted contrast agent

Indexed keywords

DISEASES; DRUG THERAPY; MAMMALS; TUMORS; ULTRASONIC APPLICATIONS; ULTRASONIC IMAGING;

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPY; CONTRAST ENHANCED ULTRASOUND; MICROBUBBLES; TARGETED CONTRAST AGENTS;

MOLECULAR IMAGING;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CONTRAST MEDIUM; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BREAST TUMOR; DRUG DELIVERY SYSTEM; ECHOGRAPHY; ECHOMAMMOGRAPHY; FEMALE; HUMAN; METHODOLOGY; MICROBUBBLE; MOLECULAR IMAGING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; MICROBUBBLES; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; ULTRASONOGRAPHY, MAMMARY;

EID: 84867221880     PISSN: 02784297     EISSN: 15509613     Source Type: Journal    
DOI: 10.7863/jum.2012.31.10.1543     Document Type: Article

References (43)

1. AmericanCancerSociety. CancerFacts& Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
3. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19:331-358.
4. National Cancer Institute. FactSheet: TargetedCancerTherapies. Bethesda, MD: USDepartmentofHealthandHumanServices, NationalInstitutes of Health; 2011.
5. KimH, FolksKD, GuoL, et al. DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol 2011; 13:94-103.
6. Hoyt K, Sorace A, Saini R. Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound. Invest Radiol 2012; 47:167-174.
7. Hoyt K, Warram JM, Umphrey H, et al. Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 2010; 29:577-585.
8. de Jong N, Frinking PJ, Bouakaz A, et al. Optical imaging of contrast agent microbubbles in an ultrasound field with a100-MHzcamera. Ultrasound Med Biol 2000; 26:487-492.
9. Calliada F, Campani R, Bottinelli O, Bozzini A, Sommaruga MG. Ultrasound contrast agents: basic principles. Eur J Radiol 1998; 27(suppl 2):S157-S160.
10. Cosgrove D. Echo enhancers and ultrasound imaging. Eur J Radiol 1997; 26:64-76.
11. Cosgrove D, Lassau N. Assessment of tumour angiogenesis using contrast-enhanced ultrasound [in French]. J Radiol 2009; 90:156-164.
12. Sorace AG, Warram JM, Umphrey H, Hoyt K. Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. J Drug Target 2012; 20:43-54.
13. Warram JM, Sorace AG, Saini R, Umphrey HR, Zinn KR, Hoyt K. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med 2011; 30:921-931.
14. DeshpandeN, RenY, FoygelK, RosenbergJ, WillmannJK. Tumorangiogenic marker expression levels during tumor growth: longitudinal assessmentwith molecularly targeted microbubbles andUSimaging. Radiology 2011; 258:804-811.
15. Eisenbrey JR, Forsberg F. Contrast-enhanced ultrasound for molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging 2010; 37(suppl 1):S138-S146.
16. Willmann JK, Cheng Z, Davis C, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008; 249:212-219.
17. Saini R, Warram JM, Sorace AG, Umphrey H, Zinn KR, Hoyt K. Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents. Ultrasound Med Biol 2011; 37: 1306-1313.
18. Zhou JH, Zheng W, Cao LH, et al. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment. Eur J Radiol 2012; 81: 1360-1365.
19. Zhou JH, Cao LH, Liu JB, et al. Quantitative assessment of tumor blood flowinmiceaftertreatmentwithdifferentdosesofanantiangiogenicagent with contrast-enhanced destruction-replenishment US. Radiology 2011; 259:406-413.
20. Forsberg F, Ro RJ, Liu JB, Lipcan KJ, Potoczek M, Nazarian LN. Monitoring angiogenesis in human melanoma xenograft model using contrast-enhanced ultrasound imaging. Ultrason Imaging 2008; 30:237-246.
21. Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 2001; 104: 2107-2112.
22. Lindner Jr. Molecular imaging with contrast ultrasound and targeted microbubbles. J Nucl Cardiol 2004; 11:215-221.
23. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008; 248:936-944.
24. Klibanov AL, Rychak JJ, Yang WC, et al. Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast Media Mol Imaging 2006; 1:259-266.
25. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-1802.
26. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29(suppl 16):3-9.
27. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. BiochemBiophysRes Commun 2005; 333:328-335.
28. StreeterJE, GessnerRC, TsurutaJ, FeingoldS, DaytonPA. Assessmentof molecular imaging of angiogenesis with three-dimensional ultrasonography. Mol Imaging 2011; 10:460-468.
29. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9(suppl 1):43-49.
30. Chen HX. Expanding the clinical development of bevacizumab. Oncologist 2004; 9(suppl 1):27-35.
31. Yang JC, Haworth L, Sherry RM, et al. Arandomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
32. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
33. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versuspaclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
34. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97:172-187.
35. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006; 24: 3299-3308.
36. Lamuraglia M, Bridal SL, Santin M, et al. Clinical relevance of contrastenhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol 2010; 73:202-212.
37. Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, Gore JC. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 2007; 26: 1575-1586.
38. Pollard RE, Broumas AR, Wisner ER, Vekich SV, Ferrara KW. Quantitative contrast enhanced ultrasoundand CT assessment of tumor response to antiangiogenic therapy in rats. UltrasoundMedBiol 2007; 33:235-245.
39. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005; 10:92-103.
40. LamuragliaM, EscudierB, ChamiL, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42: 2472-2479.
41. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16: 1216-1225.
42. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246:508-518.
43. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.